# Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yunpeng Yang,Jianji Pan,Hui Wang,Yuanyuan Zhao,Shenhong Qu,Nianyong Chen,Xiaozhong Chen,Yan Sun,Xiaohui He,Chaosu Hu,Lizhu Lin,Qitao Yu,Siyang Wang,Guihua Wang,Feng Lei,Jiyu Wen,Kunyu Yang,Zhixiong Lin,Ye Guo,Shaoqing Chen,Xiaoming Huang,Yanjie Wu,Liang Liang,Chenqi Chen,Fan Bai,Xiaopeng Ma,Yun Zhang,Shiangjiin Leaw,Li Zhang,Wenfeng Fang |
| Citations | 223 |
| DOI | 10.1016/j.ccell.2023.04.014 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.cell.com/article/S153561082300140X/pdf |
| OpenAlex ID | https://openalex.org/W4377020104 |
| PMID | 37207654 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Yunpeng Yang](https://scholariq.org/researchers/yunpeng-yang/)
- [Yuanyuan Zhao](https://scholariq.org/researchers/yuanyuan-zhao/)
- [Wenfeng Fang](https://scholariq.org/researchers/wenfeng-fang/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.